Harmony Biosciences (HRMY): Evaluating Valuation After New EPX-100 Phase 3 Data and Beacon Biosignals Collaboration
Harmony Biosciences Holdings (HRMY) just gave investors two fresh reasons to pay attention, encouraging Phase 3 extension data for EPX-100 in Dravet syndrome and a new EEG focused collaboration with Beacon Biosignals that sharpens its late stage trial readouts.
See our latest analysis for Harmony Biosciences Holdings.
Investors seem to be leaning back toward Harmony, with the recent clinical wins arriving alongside a roughly 14 percent 1 month share price return and a still negative 3 year total shareholder return. This pattern hints at ongoing sentiment repair rather than runaway momentum.
If these neurology data points have your attention, it is a good moment to scan for other potential healthcare opportunities via healthcare stocks and see what else suits your watchlist.
With shares still trading at a discount to analyst targets despite solid revenue and earnings growth, are investors overlooking Harmony’s neurology pipeline, or is the current price already baking in the next leg of growth?
Most Popular Narrative Narrative: 12.8% Undervalued
Compared with Harmony Biosciences Holdings’ last close of $38.83, the most followed narrative pegs fair value meaningfully higher, framing the current price as a potential discount rather than a ceiling.
The analysts have a consensus price target of $50.455 for Harmony Biosciences Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $70.0, and the most bearish reporting a price target of just $31.0.
Want to see what is powering this gap between today’s price and that higher fair value line? The narrative leans on accelerating earnings, expanding margins and a future profit multiple that challenges how the market currently treats mid cap neuro innovators. Curious which projections really move the needle in that model and how sensitive the outcome is to just a few core assumptions? Dive in to see what is baked into those forward looking numbers and what that could mean if they actually play out.
Result: Fair Value of $44.55 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story could unravel if WAKIX faces faster competitive erosion or if key late stage assets like ZYN002 stumble again at regulators.
Find out about the key risks to this Harmony Biosciences Holdings narrative.
Build Your Own Harmony Biosciences Holdings Narrative
If you would rather examine the numbers yourself and develop a different view of Harmony’s prospects, you can create a custom view in minutes: Do it your way.
A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Harmony Biosciences Holdings.
Looking for more investment ideas?
Before markets move on without you, put Simply Wall St to work and line up your next opportunities using focused screeners built from real fundamentals.
- Capitalize on mispriced businesses by running through these 915 undervalued stocks based on cash flows that may be trading well below their cash flow potential.
- Target future growth engines by scanning these 25 AI penny stocks shaping the next wave of automation, data intelligence and productivity gains.
- Lock in reliable portfolio income by reviewing these 13 dividend stocks with yields > 3% that combine yield with fundamentally sound balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com